Skip to main content
Premium Trial:

Request an Annual Quote

Abbott to Develop Companion Dx for Epizyme Cancer Drug Candidate

NEW YORK (GenomeWeb News) – Epizyme today said that Abbott will develop a molecular companion diagnostic test for a leukemia drug candidate that the Cambridge, Mass.-based firm is developing.

Abbott will develop a test based on its fluorescence in situ hybridization technology to detect genetic alterations of mixed lineage leukemia, an aggressive subtype of acute myeloid leukemia and acute lymphoblastic leukemia.

Epizyme is developing an inhibitor targeting the DOT1L histone methyltransferase for the treatment of mixed lineage leukemia and will use the Abbott test to detect MLL genetic alterations that lead to the oncogenic function of DOT1L.

Further terms of the alliance were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more